Safety of hormonal IUD in breast cancer patients.
作者信息
Hanne Coeman, Aurélie Foulon, Zainab Amajoud, Jan Decloedt, Femke Delporte, Maxime Van Houdt, Geert Page, Christophe Van Berckelaer
机构信息
RZ Tienen, Kliniekstraat 45, Tienen 3300, Belgium.
UZ Gent, ARG, Corneel Heymanslaan 10, Gent 9000, Belgium.
出版信息
Eur J Obstet Gynecol Reprod Biol X. 2025 Jun 30;27:100412. doi: 10.1016/j.eurox.2025.100412. eCollection 2025 Sep.
Abstract
摘要
相似文献
1
Safety of hormonal IUD in breast cancer patients.激素宫内节育器在乳腺癌患者中的安全性。
Eur J Obstet Gynecol Reprod Biol X. 2025 Jun 30;27:100412. doi: 10.1016/j.eurox.2025.100412. eCollection 2025 Sep.
2
Hormonal contraception for women at risk of HIV infection.针对有感染艾滋病毒风险的女性的激素避孕法。
Cochrane Database Syst Rev. 2025 Jun 6;6(6):CD015701. doi: 10.1002/14651858.CD015701.pub2.
3
Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy.激素浸渍宫内节育系统（IUSs）与其他形式的可逆性避孕方法作为预防妊娠的有效方法。
Cochrane Database Syst Rev. 2004;2004(3):CD001776. doi: 10.1002/14651858.CD001776.pub2.
4
Hormonally impregnated intrauterine systems (IUSs), versus other forms of reversible contraceptives as effective methods of preventing pregnancy.激素浸渍宫内节育系统（IUSs）与其他形式的可逆性避孕方法相比，是预防妊娠的有效方法。
Cochrane Database Syst Rev. 2001(2):CD001776. doi: 10.1002/14651858.CD001776.
5
Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.1型和2型糖尿病女性使用激素避孕药与非激素避孕药的情况
Cochrane Database Syst Rev. 2013 Mar 28;2013(3):CD003990. doi: 10.1002/14651858.CD003990.pub4.
6
Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery.左炔诺孕酮宫内节育系统（LNG-IUD）治疗手术后症状性子宫内膜异位症。
Cochrane Database Syst Rev. 2021 Dec 20;12(12):CD005072. doi: 10.1002/14651858.CD005072.pub4.
7
Intrauterine Contraception Device Satisfaction and Continuation in an Urban Youth Clinic in British Columbia, Canada: A Longitudinal Survey Study.加拿大不列颠哥伦比亚省一家城市青年诊所的宫内节育器满意度及持续使用情况：一项纵向调查研究
J Obstet Gynaecol Can. 2025 Jul 10;47(9):103033. doi: 10.1016/j.jogc.2025.103033.
8
Steroidal contraceptives and bone fractures in women: evidence from observational studies.甾体避孕药与女性骨折：来自观察性研究的证据
Cochrane Database Syst Rev. 2012 Aug 15(8):CD009849. doi: 10.1002/14651858.CD009849.pub2.
9
Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review.选择避孕方法启动后检测潜在不良事件的适当随访：系统评价。
Contraception. 2013 May;87(5):611-24. doi: 10.1016/j.contraception.2012.09.017. Epub 2012 Nov 21.
10
The safety of intrauterine devices in breastfeeding women: a systematic review.宫内节育器在哺乳期女性中的安全性：一项系统评价。
Contraception. 2016 Dec;94(6):725-738. doi: 10.1016/j.contraception.2016.07.006. Epub 2016 Jul 13.
本文引用的文献
1
Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems.使用左炔诺孕酮宫内节育系统的女性患乳腺癌情况
JAMA. 2024 Nov 12;332(18):1578-1580. doi: 10.1001/jama.2024.18575.
2
Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in and .激素避孕与BRCA1和BRCA2种系突变携带者的乳腺癌风险
J Clin Oncol. 2025 Feb;43(4):422-431. doi: 10.1200/JCO.24.00176. Epub 2024 Oct 2.
3
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.《NCCN 肿瘤学临床实践指南：乳腺癌》第 3.2024 版。
J Natl Compr Canc Netw. 2024 Jul;22(5):331-357. doi: 10.6004/jnccn.2024.0035.
4
Association of levonorgestrel-releasing intrauterine device with gynecologic and breast cancers: a national cohort study in Sweden.左炔诺孕酮宫内节育器与妇科和乳腺癌的关联：瑞典的一项全国队列研究。
Am J Obstet Gynecol. 2024 Oct;231(4):450.e1-450.e12. doi: 10.1016/j.ajog.2024.05.011. Epub 2024 May 15.
5
Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.青少年和青年肿瘤学（AYA），第 2.2024 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2023 Aug;21(8):851-880. doi: 10.6004/jnccn.2023.0040.
6
Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.BRCA1/2 致病性变异携带者的避孕措施与癌症风险：系统评价和荟萃分析。
Hum Reprod Update. 2023 Mar 1;29(2):197-217. doi: 10.1093/humupd/dmac038.
7
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.遗传性乳腺癌-卵巢癌综合征中癌症的风险降低与筛查：ESMO临床实践指南
Ann Oncol. 2023 Jan;34(1):33-47. doi: 10.1016/j.annonc.2022.10.004. Epub 2022 Oct 25.
8
ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5).ESO-ESMO 第五次国际年轻女性乳腺癌共识指南（BCY5）。
Ann Oncol. 2022 Nov;33(11):1097-1118. doi: 10.1016/j.annonc.2022.07.007. Epub 2022 Aug 4.
9
Influence of the levonorgestrel-releasing intrauterine system on the risk of breast cancer: a systematic review.左炔诺孕酮宫内缓释系统对乳腺癌风险的影响：系统评价。
Arch Gynecol Obstet. 2023 Jun;307(6):1747-1761. doi: 10.1007/s00404-022-06640-y. Epub 2022 Jun 18.
10
Options for Prevention and Management of Menstrual Bleeding in Adolescent Patients Undergoing Cancer Treatment: ACOG Committee Opinion, Number 817.《癌症治疗青少年患者的经期出血预防和管理选择：ACOG 委员会意见，817 号》
Obstet Gynecol. 2021 Jan 1;137(1):e7-e15. doi: 10.1097/AOG.0000000000004209.
Zotero 插件